0.59
-0.01500005(-2.50%)
Currency In USD
| Previous Close | 0.6 |
| Open | 0.63 |
| Day High | 0.65 |
| Day Low | 0.52 |
| 52-Week High | 17.98 |
| 52-Week Low | 0.26 |
| Volume | 68,088 |
| Average Volume | 814,489 |
| Market Cap | 1.99M |
| PE | -0.18 |
| EPS | -3.33 |
| Moving Average 50 Days | 0.71 |
| Moving Average 200 Days | 6.31 |
| Change | -0.02 |
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also support use of speech latency as an
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
GlobeNewswire Inc.
Dec 29, 2025 1:00 PM GMT
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
GlobeNewswire Inc.
Dec 23, 2025 1:00 PM GMT
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia Current data package hig